Amgen shares recover some oftheir losses after the companyreports no bone safety issues withits obesity drug
Amgen (NASDAQ: AMGN) saw its shares rise in premarket U.S. trading on Wednesday after the company clarified that its experimental obesity drug, MariTide, was not linked to any changes in bone mineral density. The stock had fallen more than 7% in the previous session, following a report from Cantor Fitzgerald…